Characterization of a cynomolgus macaque model of pneumonic plague for evaluation of vaccine efficacy

Clinical and Vaccine Immunology

Volumn 22, Issue 9, 2015, Pages 1070-1078

  Fellows, Patricia ^a   Price, Jessica ^a,c   Martin, Shannon ^a,d   Metcalfe, Karen ^a   Krile, Robert ^b   Barnewall, Roy ^b   Hart, Mary Kate ^a   Lockman, Hank ^b  

^a A CSC Company   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c MEDIMMUNE   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLAGUE VACCINE; RECOMBINANT VACCINE; BACTERIUM ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BREATHING RATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMORAL IMMUNITY; IMMUNIZATION; MACACA FASCICULARIS; MALE; MONKEY MODEL; NONHUMAN; PLAGUE; PRIORITY JOURNAL; SURVIVAL; VACCINATION; YERSINIA PESTIS; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; MICROBIOLOGY;

ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; MACACA FASCICULARIS; PLAGUE; PLAGUE VACCINE; VACCINES, SYNTHETIC; YERSINIA PESTIS;

EID: 84941566220     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00290-15     Document Type: Article

References (24)

1. Poland JD, Dennis DT. 1998. Plague, p 545-558. In Evans AS, Brachman PS (ed), Infectious diseases of humans: epidemiology and control, 3rd ed. Plenum, New York, NY.
2. Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, Carniel E, Gage KL, Leirs H, Rahalison L. 2008. Plague: past, present and future. PLoS Med 5:e3. http://dx.doi.org/10.1371/journal.pmed.0050003.
3. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. 2000. Plague as a biological weapon. JAMA 283:2281-2289. http://dx.doi.org/10.1001/jama.283.17.2281.
4. Centers for Disease Control and Prevention. 2010. Emergency preparedness and response. Centers for Disease Control and Prevention, Atlanta, GA. http://www.bt.cdc.gov/agent/agentlist-category.asp.
5. World Health Organization. 1970. Health aspects of chemical and biological weapons, p 98-109. World Health Organization, Geneva, Switzerland.
6. Titball RW, Williamson ED. 2004. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4:965-973. http://dx.doi.org/10.1517/14712598.4.6.965.
7. Anderson GW, Heath DG, Bolt CR, Welkos SL, Friedlander AM. 1998. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58:793-799.
8. Heath DG, Anderson GW, Maruo JM, Welkos SL, Andrews GP, Adamovicz J. 1998. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16:1131-1137. http://dx.doi.org/10.1016/S0264-410X (98) 80110-2.
9. Marshall JD, Bartelloni P, Jr, Cavanaugh DC, Kadull PJ, Meyer KF. 1974. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J Infect Dis 129(Suppl):S19-S25.
10. Meyer KF, Cavanaugh DC, Bartelloni PJ, Marshall, JD, Jr. 1974. Plague immunization. I. Past and present trends. J Infect Dis 129(Suppl):S13-S18.
11. Feodorova VA, Corbel MJ. 2009. Prospects for new plague vaccines. Expert Rev Vaccines 8:1721-1738. http://dx.doi.org/10.1586/erv. 09.129.
12. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary S E C, Oyston PC, Easterbrook T, Reddin KM, Robinson A. 1995. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12:223-230.
13. Morris SR. 2007. Development of a recombinant vaccine against aerosolized plague. Vaccine 25:3115-3117. http://dx.doi.org/10.1016/j.vaccine.2007.01.071.
14. Food and Drug Administration, HHS. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 67:37988-37998.
15. Pitt L. 2004. Nonhuman primates as a model for pneumonic plague, p 222-247. Public Workshop on Animal Models and Correlates of Protection for Plague Vaccines. Department of Health and Human Resources FDA Center for Biologics Evaluation and Research, Bethesda, MD. http://www.fda.gov/downloads/biologicsbloodvaccines/newsevents/workshops meetingsconferences/transcriptsminutes/ucm054438.pdf.
16. Adamovicz JJ, Worsham PL. 2006. Plague, p 107-135. In Swearengen JR (ed), Biodefense research methods, animal models. CRC Press, Boca Raton, FL.
17. Warren R, Lockman H, Barnewell R, Krile R, Blanco O, Vasconcelos D, Price J, House RV, Bolanowksi M, Fellows P. 2011. Cynomolgus macaque model for pneumonic plague. Microb Pathog 50:12-22. http://dx.doi.org/10.1016/j.micpath.2010.10.002.
18. Center for Drug Evaluation and Research. 2009. Guidance for industry: animal models-essential elements to address efficacy under the Animal Rule. Food and Drug Administration Department of Health and Human Services. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulato ryInformation/Guidances/UCM078923.pdf.
19. National Research Council Institute of Laboratory Animal Resources. 2011. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
20. Fellows PF, Adamovicz J, Hartings J, Sherwood R, Mega W, Brasel T, Barr E, Holland L, Lin W, Rom A, Blackwelder W, Price J, Morris S, Snow D, Hart MK. 2010. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine 28:7748-7756. http://dx.doi.org/10.1016/j.vaccine.2010.09.062.
21. Schlesinger RB. 1985. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J Toxicol Environ Health 15:197-214. http://dx.doi.org/10.1080/15287398509530647.
22. Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, Ciletti NA, Schneewind O. 2008. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 76:5588-5597. http://dx.doi.org/10.1128/IAI.00699-08.
23. Valderas MW, Overheim K, Wilder J, Zinter E, Kikendall N, Monier A, Fisher I, Brasel T, Russell R, Sherwood R, LeClair R. 2011. F1/V plague vaccine protects cynomolgus macaques but not African green monkeys from death after lethal aerosol plague challenge despite inducing a humoral response, poster 209 (H). Ninth ASM Biodefense and Emerging Diseases Research Meeting, Washington, DC. http://www.asmbiodefense.org/images/stories/bio9prgabs.pdf.
24. Quenee LE, Ciletti NA, Elli D, Hermanas TM, Schneewind O. 2011. Prevention of pneumonic plague in mice, rats, guinea pigs and nonhuman primates with clinical grade rV10, rV10-2 or F1-V. Vaccine 29:6572-6583. http://dx.doi.org/10.1016/j.vaccine.2011.06.119.